Overview

Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the effect of steady-state tipranavir 500 mg/ritonavir 200 mg (TPV/r) on intracellular concentrations of zidovudine triphosphate (ZDV-TP) and carbovir triphosphate (CBV-TP) and plasma viral load
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Carbovir
Ritonavir
Tipranavir
Zidovudine